Trial reportThe Journal of clinical endocrinology and metabolism2009
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.
Trial report in The Journal of clinical endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 142 citations in OpenAlex.
- Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days.The Journal of clinical endocrinology and metabolism · 2021Trial
- Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects.Frontiers in endocrinology · 2020Trial
- Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men.The Journal of clinical endocrinology and metabolism · 2016Trial
- Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.The Journal of clinical investigation · 2016Trial
- Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial.Andrology · 2016Trial
- Trial
- Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.The Journal of clinical endocrinology and metabolism · 2011Trial
- Review
- Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?International journal of molecular sciences · 2025Review
- Diagnosis and treatment of hypogonadism in men seeking to preserve fertility - what are the options?International journal of impotence research · 2025Review
- Selective androgen receptor modulators: a critical appraisal.Frontiers in endocrinology · 2025Review
- Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial.Journal of the Endocrine Society · 2024Article
- Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.Nature reviews. Endocrinology · 2023Review
- Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.Pituitary · 2021Article
- Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.Journal of general internal medicine · 2021Review
- Testosterone and Bone Health in Men: A Narrative Review.Journal of clinical medicine · 2021Review
- Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: The Cardiovascular Health Study.Metabolism: clinical and experimental · 2021Article
- Nonsurgical Management of Oligozoospermia.The Journal of clinical endocrinology and metabolism · 2020Article
- Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members.Urology · 2020Article
- Non-testosterone management of male hypogonadism: an examination of the existing literature.Translational andrology and urology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
contextAging is associated with declining gonadal steroid production, low bone mineral density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in older men remains uncertain.
objectiveThe objective of the study was to assess the effects of aromatase inhibition on BMD in older men with low testosterone levels. DESIGN AND
settingThis was a 1-yr, double-blind, randomized, placebo-controlled trial that was conducted at a tertiary care academic center in Boston, MA.
participantsParticipants included 69 men aged 60+ yr with borderline or low testosterone levels and hypogonadal symptoms.
interventionIntervention included 1 mg anastrozole daily or placebo.
main outcome measuresChanges in gonadal steroid hormone levels, BMD, and bone turnover markers were measured.
resultsMean serum testosterone increased from 319 +/- 93 ng/dl at baseline to 524+/-139 ng/dl at month 3 (P < 0.0001) and declined slightly to 474 +/- 145 ng/dl by 1 yr. Estradiol levels decreased from 15 +/- 4 pg/ml at baseline to 12 +/- 4 pg/ml at month 3 and then remained stable (P < 0.0001). Posterior-anterior (PA) spine BMD decreased in the anastrozole group as compared with placebo (P = 0.0014). In the anastrozole group, PA spine BMD decreased from 1.121 +/- 0.141 g/cm(2) to 1.102 +/- 0.138 g/cm(2), whereas in the placebo group, PA spine BMD increased from 1.180 +/- 0.145 g/cm(2) to 1.189 +/- 0.146 g/cm(2). Qualitatively similar, but not statistically significant, changes occurred at the other sites. Bone turnover markers were not affected by anastrozole therapy.
conclusionsIn older men, aromatase inhibition increases testosterone levels, decreases estradiol levels, and appears to decrease BMD. Aromatase inhibition does not improve skeletal health in aging men with low or low normal testosterone levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.